Using Trastuzumab Emtansine after Trastuzumab Deruxtecan for HER2-Positive Breast Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the effectiveness of trastuzumab emtansine (T-DM1) administered immediately after trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive breast cancer in Korea. The study aims to evaluate the outcomes of patients who have progressed on T-DXd and are treated with T-DM1 as their next line of therapy. Participants must have previously received T-DXd and meet specific eligibility criteria regarding their treatment history. The study will provide insights into the sequential use of these therapies in managing advanced breast cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer
* Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting
* Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression

Exclusion Criteria:

* Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)
* Has been previously treated with T-DM1 for advanced breast cancer
* Has been previously treated with 4 or more lines of therapy for advanced breast cancer

  * Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).

Where it's running

• Seoul National University Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Kyung-Hun Lee, MD, PhD
• Email: kyunghunlee@snu.ac.kr
• Phone: 82-2-2072-7207

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Trastuzumab deruxtecan for Russian patients with HER2-positive unresectable or metastatic breast cancer

  This study will see how well trastuzumab deruxtecan (T-DXd) works in Russian adults with unresectable or metastatic HER2-positive breast cancer who received at least one cycle.

  Recruiting Blokhin's Russian Cancer Research Center · Moscow · NCT07281001

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Navigation help for breast cancer patients with social needs

  This study tests a patient navigator program to connect breast cancer patients with unmet social needs to community resources.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07781800

• Trastuzumab Rezetecan and Gemcitabine before surgery for HER2-positive UTUC

  This study tests whether giving trastuzumab deruxtecan with gemcitabine before and around surgery can improve outcomes for people with HER2-positive upper tract urothelial cancer.

  Recruiting at 10 sites Phase 2 Tongji Hospital · Huanggang, Hubei and 9 other locations · NCT07741448

• Foslorapitant with Palonosetron to Help Prevent Nausea and Vomiting from Trastuzumab Rezetecan

  A single-arm study tests whether giving foslorapitant plus palonosetron can prevent chemotherapy-induced nausea and vomiting in adults receiving Trastuzumab Rezetecan.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07726433

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.